{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:43:26Z","timestamp":1768347806252,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["FE 1282\/2-1"],"award-info":[{"award-number":["FE 1282\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["GRK2099\/RTG2099"],"award-info":[{"award-number":["GRK2099\/RTG2099"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"crossref","award":["FKZ 02NUK036A"],"award-info":[{"award-number":["FKZ 02NUK036A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00262-018-2171-7","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T11:54:26Z","timestamp":1527162866000},"page":"1147-1157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin"],"prefix":"10.1007","volume":"67","author":[{"given":"Corinne","family":"Bauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashik Ahmed","family":"Abdul Pari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Umansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Boukamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hellmut G.","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergij","family":"Goerdt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrill","family":"G\u00e9raud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Felcht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"2171_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamadermatol.2013.2139","volume":"149","author":"CD Schmults","year":"2013","unstructured":"Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA (2013) Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 149:541\u2013547. \n                    https:\/\/doi.org\/10.1001\/jamadermatol.2013.2139","journal-title":"JAMA Dermatol"},{"key":"2171_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","volume":"68","author":"PS Karia","year":"2013","unstructured":"Karia PS, Han J, Schmults CD (2013) Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 68:957\u2013966. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2012.11.037","journal-title":"J Am Acad Dermatol"},{"key":"2171_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2147\/CLEP.S99464","volume":"8","author":"AL Lamberg","year":"2016","unstructured":"Lamberg AL, Solvsten H, Lei U et al (2016) The Danish nonmelanoma skin cancer dermatology database. Clin Epidemiol 8:633\u2013636. \n                    https:\/\/doi.org\/10.2147\/CLEP.S99464","journal-title":"Clin Epidemiol"},{"key":"2171_CR4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","volume":"151","author":"HW Rogers","year":"2015","unstructured":"Rogers HW, Weinstock MA, Feldman SR, Coldiron BM (2015) Incidence estimate of nonmelanoma skin cancer (Keratinocyte Carcinomas) in the US population, 2012. JAMA Dermatol 151:1081\u20131086. \n                    https:\/\/doi.org\/10.1001\/jamadermatol.2015.1187","journal-title":"JAMA Dermatol"},{"key":"2171_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00105-017-3951-2","volume":"68","author":"A Lobeck","year":"2017","unstructured":"Lobeck A, Weiss C, Orouji A et al. (2017) Single center analysis of the dermatosurgical patient cohort of a tumor center in Germany. Hautarzt 68:377\u2013384. \n                    https:\/\/doi.org\/10.1007\/s00105-017-3951-2","journal-title":"Hautarzt"},{"key":"2171_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamadermatol.2015.4994","volume":"152","author":"AK Thompson","year":"2016","unstructured":"Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL (2016) Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol 152:419\u2013428. \n                    https:\/\/doi.org\/10.1001\/jamadermatol.2015.4994","journal-title":"JAMA Dermatol"},{"key":"2171_CR7","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1038\/sj.onc.1209474","volume":"25","author":"B Burnworth","year":"2006","unstructured":"Burnworth B, Popp S, Stark HJ, Steinkraus V, Brocker EB, Hartschuh W, Birek C, Boukamp P (2006) Gain of 11q\/cyclin D1 overexpression is an essential early step in skin cancer development and causes abnormal tissue organization and differentiation. Oncogene 25:4399\u20134412. \n                    https:\/\/doi.org\/10.1038\/sj.onc.1209474","journal-title":"Oncogene"},{"key":"2171_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/exd.12880","volume":"25","author":"T Gleich","year":"2016","unstructured":"Gleich T, Chiticariu E, Huber M, Hohl D (2016) Keratoacanthoma: a distinct entity? Exp Dermatol 25:85\u201391. \n                    https:\/\/doi.org\/10.1111\/exd.12880","journal-title":"Exp Dermatol"},{"key":"2171_CR9","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jaad.2015.11.033","volume":"74","author":"B Kwiek","year":"2016","unstructured":"Kwiek B, Schwartz RA (2016) Keratoacanthoma (KA): an update and review. J Am Acad Dermatol 74:1220\u20131233. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2015.11.033","journal-title":"J Am Acad Dermatol"},{"key":"2171_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/his.13018","volume":"69","author":"J Selmer","year":"2016","unstructured":"Selmer J, Skov T, Spelman L, Weedon D (2016) Squamous cell carcinoma and keratoacanthomas are biologically distinct and can be diagnosed by light microscopy: a review. Histopathology 69:535\u2013541. \n                    https:\/\/doi.org\/10.1111\/his.13018","journal-title":"Histopathology"},{"issue":"Suppl 2","key":"2171_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jdv.14092","volume":"31","author":"E Stockfleth","year":"2017","unstructured":"Stockfleth E (2017) The importance of treating the field in actinic keratosis. J Eur Acad Dermatol Venereol 31(Suppl 2):8\u201311. \n                    https:\/\/doi.org\/10.1111\/jdv.14092","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 2","key":"2171_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jdv.14151","volume":"31","author":"MT Fernandez Figueras","year":"2017","unstructured":"Fernandez Figueras MT (2017) From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol 31(Suppl 2):5\u20137. \n                    https:\/\/doi.org\/10.1111\/jdv.14151","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2171_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.0303-6987.2006.00516.x","volume":"33","author":"DS Cassarino","year":"2006","unstructured":"Cassarino DS, Derienzo DP, Barr RJ (2006) Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification\u2014part two. J Cutan Pathol 33:261\u2013279. \n                    https:\/\/doi.org\/10.1111\/j.0303-6987.2006.00516.x","journal-title":"J Cutan Pathol"},{"key":"2171_CR14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/modpathol.2011.39","volume":"24","author":"SH Ra","year":"2011","unstructured":"Ra SH, Li X, Binder S (2011) Molecular discrimination of cutaneous squamous cell carcinoma from actinic keratosis and normal skin. Mod Pathol 24:963\u2013973. \n                    https:\/\/doi.org\/10.1038\/modpathol.2011.39","journal-title":"Mod Pathol"},{"key":"2171_CR15","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1126\/science.aaa6806","volume":"348","author":"I Martincorena","year":"2015","unstructured":"Martincorena I, Roshan A, Gerstung M et al (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348:880\u2013886. \n                    https:\/\/doi.org\/10.1126\/science.aaa6806","journal-title":"Science"},{"key":"2171_CR16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.14852","volume":"177","author":"JA Siegel","year":"2017","unstructured":"Siegel JA, Korgavkar K, Weinstock MA (2017) Current perspective on actinic keratosis: a review. Br J Dermatol 177:350\u2013358. \n                    https:\/\/doi.org\/10.1111\/bjd.14852","journal-title":"Br J Dermatol"},{"key":"2171_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235\u2013271. \n                    https:\/\/doi.org\/10.1146\/annurev-immunol-031210-101324","journal-title":"Annu Rev Immunol"},{"key":"2171_CR18","doi-asserted-by":"publisher","first-page":"624123","DOI":"10.1155\/2013\/624123","volume":"2013","author":"VR Yanofsky","year":"2013","unstructured":"Yanofsky VR, Mitsui H, Felsen D, Carucci JA (2013) Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy. Clin Dev Immunol. 2013:624123. \n                    https:\/\/doi.org\/10.1155\/2013\/624123","journal-title":"Clin Dev Immunol"},{"key":"2171_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","volume":"25","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S (2013) Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 25:268\u2013276. \n                    https:\/\/doi.org\/10.1016\/j.coi.2013.02.009","journal-title":"Curr Opin Immunol"},{"key":"2171_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12916-017-0879-4","volume":"15","author":"P Szturz","year":"2017","unstructured":"Szturz P, Vermorken JB (2017) Immunotherapy in head and neck cancer: aiming at EXTREME precision. BMC Med 15:110. \n                    https:\/\/doi.org\/10.1186\/s12916-017-0879-4","journal-title":"BMC Med"},{"key":"2171_CR21","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1038\/jid.2009.96","volume":"129","author":"MJ Bluth","year":"2009","unstructured":"Bluth MJ, Zaba LC, Moussai D et al (2009) Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J Invest Dermatol 129:2451\u20132462. \n                    https:\/\/doi.org\/10.1038\/jid.2009.96","journal-title":"J Invest Dermatol"},{"key":"2171_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2340\/00015555-1597","volume":"93","author":"Y Kambayashi","year":"2013","unstructured":"Kambayashi Y, Fujimura T, Aiba S (2013) Comparison of immunosuppressive and immunomodulatory cells in keratoacanthoma and cutaneous squamous cell carcinoma. Acta Derm Venereol 93:663\u2013668. \n                    https:\/\/doi.org\/10.2340\/00015555-1597","journal-title":"Acta Derm Venereol"},{"issue":"Suppl 1","key":"2171_CR23","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/S0140-6736(15)60374-9","volume":"385","author":"C Lai","year":"2015","unstructured":"Lai C, August S, Behar R, Polak M, Ardern-Jones M, Theaker J, Al-Shamkhani A, Healy E (2015) Characteristics of immunosuppressive regulatory T cells in cutaneous squamous cell carcinomas and role in metastasis. Lancet 385 (Suppl 1):S59. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)60374-9","journal-title":"Lancet"},{"key":"2171_CR24","doi-asserted-by":"publisher","first-page":"81341","DOI":"10.18632\/oncotarget.13228","volume":"7","author":"AK Mishra","year":"2016","unstructured":"Mishra AK, Kadoishi T, Wang X, Driver E, Chen Z, Wang XJ, Wang JH (2016) Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. Oncotarget 7:81341\u201381356. \n                    https:\/\/doi.org\/10.18632\/oncotarget.13228","journal-title":"Oncotarget"},{"key":"2171_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00262-017-2015-x","volume":"66","author":"T Gambichler","year":"2017","unstructured":"Gambichler T, Gnielka M, Ruddel I, Stockfleth E, Stucker M, Schmitz L (2017) Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. Cancer Immunol Immunother 66:1199\u20131204. \n                    https:\/\/doi.org\/10.1007\/s00262-017-2015-x","journal-title":"Cancer Immunol Immunother"},{"key":"2171_CR26","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M et al (2017) IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930\u20132940. \n                    https:\/\/doi.org\/10.1172\/JCI91190","journal-title":"J Clin Invest"},{"key":"2171_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/cei.12921","volume":"188","author":"Q Jiao","year":"2017","unstructured":"Jiao Q, Liu C, Li W, Li W, Fang F, Qian Q, Zhang X (2017) Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour-infiltrating dendritic cells. Clin Exp Immunol 188:420\u2013429. \n                    https:\/\/doi.org\/10.1111\/cei.12921","journal-title":"Clin Exp Immunol"},{"key":"2171_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jamadermatol.2016.5118","volume":"153","author":"ML Stevenson","year":"2017","unstructured":"Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, Krueger JG, Pavlick AC, Carucci JA (2017) Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol 153:299\u2013303. \n                    https:\/\/doi.org\/10.1001\/jamadermatol.2016.5118","journal-title":"JAMA Dermatol"},{"key":"2171_CR29","doi-asserted-by":"publisher","first-page":"e0175755","DOI":"10.1371\/journal.pone.0175755","volume":"12","author":"R Linedale","year":"2017","unstructured":"Linedale R, Schmidt C, King BT, Ganko AG, Simpson F, Panizza BJ, Leggatt GR (2017) Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients. PLoS One 12:e0175755. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0175755","journal-title":"PLoS One"},{"key":"2171_CR30","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1111\/ajt.14382","volume":"17","author":"A Mittal","year":"2017","unstructured":"Mittal A, Colegio OR (2017) Skin cancers in organ transplant recipients. Am J Transplant 17:2509\u20132530. \n                    https:\/\/doi.org\/10.1111\/ajt.14382","journal-title":"Am J Transplant"},{"key":"2171_CR31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2010.12.038","volume":"66","author":"RH Rosen","year":"2012","unstructured":"Rosen RH, Gupta AK, Tyring SK (2012) Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol 66:486\u2013493. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2010.12.038","journal-title":"J Am Acad Dermatol"},{"key":"2171_CR32","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/ncomms2566","volume":"4","author":"A Walter","year":"2013","unstructured":"Walter A, Schafer M, Cecconi V et al (2013) Aldara activates TLR7-independent immune defence. Nat Commun 4:1560. \n                    https:\/\/doi.org\/10.1038\/ncomms2566","journal-title":"Nat Commun"},{"key":"2171_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri.2016.80","volume":"16","author":"DE Speiser","year":"2016","unstructured":"Speiser DE, Ho PC, Verdeil G (2016) Regulatory circuits of T cell function in cancer. Nat Rev Immunol 16:599\u2013611. \n                    https:\/\/doi.org\/10.1038\/nri.2016.80","journal-title":"Nat Rev Immunol"},{"key":"2171_CR34","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF (2013) Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5:200ra116. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3006504","journal-title":"Sci Transl Med"},{"key":"2171_CR35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. \n                    https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"2171_CR36","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014\u20131022. \n                    https:\/\/doi.org\/10.1038\/ni.2703","journal-title":"Nat Immunol"},{"key":"2171_CR37","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","volume":"14","author":"T Okazaki","year":"2013","unstructured":"Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T (2013) A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14:1212\u20131218. \n                    https:\/\/doi.org\/10.1038\/ni.2762","journal-title":"Nat Immunol"},{"key":"2171_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/PPO.0000000000000059","volume":"20","author":"VA Boussiotis","year":"2014","unstructured":"Boussiotis VA, Chatterjee P, Li L (2014) Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J 20:265\u2013271. \n                    https:\/\/doi.org\/10.1097\/PPO.0000000000000059","journal-title":"Cancer J"},{"key":"2171_CR39","isbn-type":"print","first-page":"702","volume-title":"Skin tumors. Weedon\u2019s skin pathology","author":"D Weedon","year":"2009","unstructured":"Weedon D (2009) Skin tumors. Weedon\u2019s skin pathology. 3rd\u00a0edn. London: Churchill Livingstone, pp\u00a0702\u2013708. ISBN 9780702047749","ISBN":"https:\/\/id.crossref.org\/isbn\/9780702047749","edition":"3"},{"key":"2171_CR40","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1365-2133.2012.10987.x","volume":"167","author":"M Felcht","year":"2012","unstructured":"Felcht M, Heck M, Weiss C et al. (2012) Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells. Br J Dermatol 167:348\u2013358. \n                    https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10987.x","journal-title":"Br J Dermatol"},{"key":"2171_CR41","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/cup.12728","volume":"43","author":"NA Slater","year":"2016","unstructured":"Slater NA, Googe PB (2016) PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. J Cutan Pathol 43:663\u2013670. \n                    https:\/\/doi.org\/10.1111\/cup.12728","journal-title":"J Cutan Pathol"},{"key":"2171_CR42","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaad.2017.05.047","volume":"77","author":"JM Garcia-Pedrero","year":"2017","unstructured":"Garcia-Pedrero JM, Martinez-Camblor P, Diaz-Coto S, Munguia-Calzada P, Vallina-Alvarez A, Vazquez-Lopez F, Rodrigo JP, Santos-Juanes J (2017) Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol 77:527\u2013533. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2017.05.047","journal-title":"J Am Acad Dermatol"},{"key":"2171_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.pathol.2017.04.004","volume":"49","author":"E Roper","year":"2017","unstructured":"Roper E, Lum T, Palme CE, Ashford B, Ch\u2019ng S, Ranson M, Boyer M, Clark J, Gupta R (2017) PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology 49:499\u2013505. \n                    https:\/\/doi.org\/10.1016\/j.pathol.2017.04.004","journal-title":"Pathology"},{"key":"2171_CR44","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","volume":"4","author":"MM Awad","year":"2016","unstructured":"Awad MM, Jones RE, Liu H et al (2016) Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors. Cancer Immunol Res 4:1038\u20131048. \n                    https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0171","journal-title":"Cancer Immunol Res"},{"key":"2171_CR45","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7150\/jca.14549","volume":"7","author":"Z Li","year":"2016","unstructured":"Li Z, Dong P, Ren M, Song Y, Qian X, Yang Y, Li S, Zhang X, Liu F (2016) PD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patient. J Cancer 7:784\u2013793. \n                    https:\/\/doi.org\/10.7150\/jca.14549","journal-title":"J Cancer"},{"key":"2171_CR46","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/modpathol.2017.79","volume":"30","author":"ED Thompson","year":"2017","unstructured":"Thompson ED, Taube JM, Asch-Kendrick RJ et al (2017) PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Mod Pathol 30:1551\u20131560. \n                    https:\/\/doi.org\/10.1038\/modpathol.2017.79","journal-title":"Mod Pathol"},{"key":"2171_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-017-0270-y","author":"O Stasikowska-Kanicka","year":"2017","unstructured":"Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M (2017) Immunohistochemical analysis of Foxp3+, CD4+, CD8 + cell infiltrates and PD-L1 in oral squamous cell carcinoma. Pathol Oncol Res doi. \n                    https:\/\/doi.org\/10.1007\/s12253-017-0270-y","journal-title":"Pathol Oncol Res doi"},{"key":"2171_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1172\/JCI89820","volume":"127","author":"TJ Cunningham","year":"2017","unstructured":"Cunningham TJ, Tabacchi M, Eliane JP et al (2017) Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest 127:106\u2013116. \n                    https:\/\/doi.org\/10.1172\/JCI89820","journal-title":"J Clin Invest"},{"key":"2171_CR49","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1158\/1078-0432.CCR-15-2614","volume":"22","author":"C Lai","year":"2016","unstructured":"Lai C, August S, Albibas A et al (2016) OX40 + regulatory T cells in cutaneous squamous cell carcinoma suppress effector T-cell responses and associate with metastatic potential. Clin Cancer Res 22:4236\u20134248. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2614","journal-title":"Clin Cancer Res"},{"key":"2171_CR50","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1097\/TP.0000000000001759","volume":"101","author":"E Crespo","year":"2017","unstructured":"Crespo E, Fernandez L, Lucia M et al (2017) Effector antitumor and regulatory T cell responses influence the development of nonmelanoma skin cancer in kidney transplant patients. Transplantation 101:2102\u20132110. \n                    https:\/\/doi.org\/10.1097\/TP.0000000000001759","journal-title":"Transplantation"},{"key":"2171_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S (2017) Regulatory T cells in cancer immunotherapy. Cell Res 27:109\u2013118. \n                    https:\/\/doi.org\/10.1038\/cr.2016.151","journal-title":"Cell Res"},{"key":"2171_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bjd.13172","volume":"172","author":"B Azzimonti","year":"2015","unstructured":"Azzimonti B, Zavattaro E, Provasi M, Vidali M, Conca A, Catalano E, Rimondini L, Colombo E, Valente G (2015) Intense Foxp3+ CD25+ regulatory T-cell infiltration is associated with high-grade cutaneous squamous cell carcinoma and counterbalanced by CD8+\/Foxp3+ CD25+ ratio. Br J Dermatol 172:64\u201373. \n                    https:\/\/doi.org\/10.1111\/bjd.13172","journal-title":"Br J Dermatol"},{"key":"2171_CR53","doi-asserted-by":"publisher","first-page":"e08133","DOI":"10.7554\/eLife.08133","volume":"5","author":"M Baas","year":"2016","unstructured":"Baas M, Besancon A, Goncalves T et al (2016) TGFbeta-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance. Elife 5:e08133. \n                    https:\/\/doi.org\/10.7554\/eLife.08133","journal-title":"Elife"},{"key":"2171_CR54","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/ng.780","volume":"43","author":"DR Goudie","year":"2011","unstructured":"Goudie DR, D\u2019Alessandro M, Merriman B et al (2011) Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat Genet 43:365\u2013369. \n                    https:\/\/doi.org\/10.1038\/ng.780","journal-title":"Nat Genet"},{"key":"2171_CR55","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00262-015-1653-0","volume":"64","author":"ME Lacouture","year":"2015","unstructured":"Lacouture ME, Morris JC, Lawrence DP et al (2015) Cutaneous keratoacanthomas\/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol Immunother 64:437\u2013446. \n                    https:\/\/doi.org\/10.1007\/s00262-015-1653-0","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2171-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2171-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2171-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:10:22Z","timestamp":1558638622000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2171-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2171"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2171-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,24]]},"assertion":[{"value":"21 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Moritz Felcht received travel and congress participation funding by TEVA company, honoraria as an advisory board member of AbbVie Ltd. and lecture fees by Periderm GmbH and Mibe Vertrieb GmbH. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed with archived paraffin-embedded tissue samples. The study was approved by the ethical committee II of Heidelberg University (2014-835R-MA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Informed consent by individual patients cannot be given, as the study only included paraffin-embedded archived tissue. With the approval of the ethical committee informed consent was not required as all patient data were anonymized.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}